|
See related Depo-Provera 150 inj information |
|
|
|
Manufacturer |
Pfizer |
|
Distributor |
Hong Kong: Primal/Macau: The Glory Medicina |
|
Contents |
Medroxyprogesterone acetate |
|
Indications |
Prevention of pregnancy.
Click to view Depo-Provera 150 detailed prescribing infomation |
|
Dosage |
IM 150 mg every 3 mth.
Click to view Depo-Provera 150 detailed prescribing infomation |
|
Contraindications |
Known or suspected pregnancy or as a diagnostic test for pregnancy. Active thrombophlebitis, current or history of thromboembolic disorders or cerebral vascular disease. Known or suspected malignancy of breast. Significant liver disease. Undiagnosed vag bleeding.
Click to view Depo-Provera 150 detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Depo-Provera 150 detailed prescribing infomation |
|
Special Precautions |
Loss of bone mineral density, thromboembolic disorders, breast & cervical cancer, anaphylaxis & anaphylactoid reaction, renal & hepatic impairment, convulsion, history of depression, bleeding irregularities. Wt gain, decreased glucose tolerance. Monitor patients w/ diabetes, epilepsy, migraine, asthma, cardiac dysfunction. STD. Pregnancy (including ectopic) & lactation. Elderly. Childn.
Click to view Depo-Provera 150 detailed prescribing infomation |
|
Adverse Drug Reactions |
Bleeding, amenorrhea, increased wt, headache, abdominal pain/discomfort, nervousness, dizziness, decreased libido.
View ADR Monitoring Form |
|
Drug Interactions |
Barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's wort, topiramate, HIV-protease inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs). Aminoglutethimide.
View more drug interactions with Depo-Provera 150 |
|
Pregnancy Category (US FDA) |
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. |
|
Storage |
View Depo-Provera 150 storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Depo-Provera 150 description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Depo-Provera 150 mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
ATC Classification |
G03AC06 - medroxyprogesterone ; Belongs to the class of progestogens. Used as systemic contraceptives. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Depo-Provera 150 injection |
|
Depo-Provera 150 (vial) 150 mg/1 mL x 1 mL |
|
|
|
Manufacturer: |
Pfizer |
|
Distributor: |
Hong Kong: Primal
Macau: The Glory Medicina
|
|
|
|
